Table 4

Antitumor activity of ZD1839 and platinum compounds given alone or in combination against human lung tumors xenografted to nude mice

Two to three experiments of three to four mice/group.

TumorDrug compoundaAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
A549+113.1 ± 2+11850 /8
ZD1839 (75)−69.9 ± 1+5270 /8
CDDP (1.5)−27.7 ± 2+1890 /8
CBCDA (50)−17.4 ± 2+1680 /8
ZD1839+ CDDP−75.6 ± 1+410 /8
ZD1839+ CBCDA−85.9 ± 1+380 /8
LX-1−415.2 ± 1+18010 /9
ZD1839 (75)−712.2 ± 2+9560 /9
CBCDA (50)+110.2 ± 1+5450 /9
ZD1839 + CBCDA−77.4 ± 2+1880 /9
  • a ZD1839 given (qd × 5) × 2 and platinums given every 3–4 days × 4 at 3–4 days after transplant.

  • b Initial tumor mass was 50–65 mg (4.8 ± 0.2 mm diameter).

  • c Measurements made 2–3 days after dose.